Posters
Multifocal intraocular presbyopia correction, binocularity level and neuroplasticity
Poster Details
First Author: O.Rozanova RUSSIA
Co Author(s): A. Shchuko
Abstract Details
Purpose:
To reveal the influence of the brain ability in double images fusion on the results of multifocal intraocular presbyopia correction.
Setting:
S. Fyodorov Eye Microsurgery State Institution, Irkutsk branch, Russia.
Methods:
The prospective analysis was done in patients with presbyopia and initial lenticular opacities before and after phacoemulsification with bilateral �.00 D IOLs AcrySof ReSTOR SN6AD1 implantation (n=60/120 eyes). The visual acuity logMAR 0.2 and better, the age from 45 to 55 years, the absence of concomitant ophthalmo- and neuropathology, the achievement of target refraction were inclusion criteria. The treatment directed to activate the binocularity was done 3 months after the operation. The visual acuity, the contrast sensitivity (CS), the stereoperception, the fusion limits, the evoked visual potentials (EVP), the critical flicker fusion threshold (CFFT), the vision quality (VF-14) were investigated.
Results:
The brain ability in double images fusion was decreased in 78% cases and it was extremely reduced (10 times and more) in 6% cases. The postoperative values of visual acuity, CS, vision quality correlated with the individual binocularity level. The increase of the visual acuity, CS (6, 12, 18 cpd), stereoperception, CFFT, visual quality and the EVP implicit time decrease were estimated after the binocularity activation treatment (Wilcoxon p<0.05). The individual degree (��) of the fusion area increase had strong correlations with distance visual acuity (r= -0.67, p=0.001), CS 18 cpd (r=0.35, p=0.01) and quality of vision (r=0.81, p=0.0001).
Conclusions:
The vision quality in patients with multifocal IOLs has strong relationships with the fusional field area and the individual degree of the binocularity level increase in binocularity activation treatment, in other words with the individual neuroplasticity.
Financial Disclosure:
NONE
